rs33980500 — TRAF3IP2 D10N

Missense variant in Act1 that abolishes IL-17 signaling by disrupting TRAF6 binding, driving paradoxical hyperactivation of Th17 responses and psoriasis susceptibility

See your personal result for TRAF3IP2

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

TRAF3IP2 D10N — The IL-17 Signaling Switch at the Heart of Psoriasis

TRAF3IP2 encodes Act1 (also called CIKS — connector of kinase to stress-activated protein kinase), the essential adaptor protein11 essential adaptor protein
Act1 is recruited to the cytoplasmic domain of the IL-17 receptor complex upon IL-17A or IL-17F binding that bridges IL-17 receptor activation to downstream inflammatory gene expression. When IL-17 binds its receptor on keratinocytes, fibroblasts, and mucosal epithelial cells, Act1 assembles a signaling scaffold that recruits TRAF6 and ultimately activates NF-κB — the master switch for pro-inflammatory cytokines including IL-6, IL-8, CXCL1, and GM-CSF. The D10N variant disrupts this scaffold at its very foundation, producing consequences that are paradoxical and clinically important.

The Mechanism

Aspartic acid at position 10 of Act1 is required for two critical interactions: binding to the molecular chaperone Hsp9022 binding to the molecular chaperone Hsp90
Act1 is an obligate client protein of Hsp90; the chaperone stabilizes Act1 and directs its proper folding and activity, and binding to TRAF6, TRAF2, and TRAF3. The D10N substitution (aspartic acid → asparagine, a conservative but chemically critical change) abolishes both interactions simultaneously.

Without Hsp90 regulation, D10N Act1 loses its ability to engage any known IL-17 signaling component33 D10N Act1 loses its ability to engage any known IL-17 signaling component
D10N-reconstituted Act1-deficient cells fail to activate IκBα phosphorylation, Erk/Jnk, or NF-κB upon IL-17 stimulation — it cannot bind IL-17 receptor, TRAF6, TRAF2, TRAF3, or IKKi. Functional assays demonstrated near-complete disruption of TRAF6 binding44 near-complete disruption of TRAF6 binding
Full-length TRAF3IP2 construct containing D10N showed a nearly completely disrupted interaction with TRAF6 compared to wild-type Act1, making it effectively a loss-of-function allele in the IL-17 pathway.

The paradox: losing IL-17 signaling through Act1 should dampen inflammation. Instead, Act1-null mice develop spontaneous skin inflammation driven by IL-2255 Act1-null mice develop spontaneous skin inflammation driven by IL-22
In the absence of IL-17-mediated signaling, IL-22 becomes the dominant inflammatory cytokine and T-cell-intrinsic Act1 loss causes hyper-Th17 responses. IL-17 signaling normally provides a negative feedback on Th17 cell expansion. When Act1 is non-functional, this brake is removed, Th17 cells proliferate excessively, and IL-22-driven keratinocyte hyperproliferation — the hallmark of psoriatic plaques — ensues.

The Evidence

Two independent genome-wide association studies published simultaneously in 2010 established TRAF3IP2 as a major psoriasis susceptibility locus. The coding variant rs33980500 showed combined P=1.13×10⁻²⁰ with OR=1.9566 combined P=1.13×10⁻²⁰ with OR=1.95
Discovery cohort of 609 German PsA cases plus replication in 6 European cohorts totaling 5,488 individuals — one of the strongest non-HLA associations in psoriasis genetics. A concurrent GWAS77 concurrent GWAS
Independent US/Canadian cohort with 6,487 cases and 8,037 controls, combined P=1.24×10⁻¹⁶ confirmed the association, with OR for psoriatic arthritis reaching 1.57 (95% CI 1.38–1.78).

The T risk allele shows marked ancestry stratification88 marked ancestry stratification
Variant absent in Han Chinese; frequency ~7.4% European, ~14.2% African, ~1.1% East Asian: common in European and African populations but nearly absent in East Asian populations, where psoriasis has a different genetic architecture. This population difference explains why TRAF3IP2 associations were discovered in European cohorts.

Neutrophil extracellular traps (NETs) — DNA-protein webs released by activated neutrophils99 Neutrophil extracellular traps (NETs) — DNA-protein webs released by activated neutrophils
NETs are abundant in psoriatic lesions and known to trigger Th17 differentiation via TLR2 and TLR4 activation interact with D10N genotype in a dose-dependent manner: in the presence of spontaneous NETs, both Th17 percentages and IL-17A release were significantly more pronounced in D10N homozygotes than wild-type, linking innate immune triggers specifically to the D10N genotype.

Practical Implications

The D10N variant has two clinical dimensions: disease susceptibility and treatment pharmacogenomics.

For disease risk, T allele carriers have 1.3-fold (heterozygous) to 1.95-fold (homozygous) elevated baseline risk for psoriasis vulgaris and psoriatic arthritis. The variant predisposes to the IL-22-driven keratinocyte proliferation and plaque formation characteristic of psoriasis. Psoriasis triggers — skin trauma (Koebner phenomenon), streptococcal infections, certain medications (beta-blockers, lithium, antimalarials), and obesity — are especially relevant for T allele carriers.

For anti-IL-17 biologic therapy (secukinumab, ixekizumab, brodalumab), the D10N variant has pharmacogenomic significance. Because these drugs block IL-17A or the IL-17 receptor, and because D10N carriers already have impaired IL-17 downstream signaling, the therapeutic pathway is partially pre-disrupted. One pharmacogenomic analysis found that TRAF3IP2_v1 allele absence was associated with better secukinumab response1010 TRAF3IP2_v1 allele absence was associated with better secukinumab response
HLA-Cw6+ patients responded significantly better to secukinumab depending on TRAF3IP2_v1 allele absence in HLA-Cw6+ patients. For TNF-inhibitor therapy1111 TNF-inhibitor therapy
163 PsA patients; TRAF3IP2 variant allele carriers showed better DAPsA score improvement on TNF-inhibitors at 22 and 54 weeks, suggesting the variant modifies biologic treatment response, D10N carriers showed improved joint inflammation outcomes.

Psoriatic skin, when present, should be evaluated for joint involvement (psoriatic arthritis affects ~30% of psoriasis patients); early detection matters because joint damage is progressive.

Interactions

The TRAF3IP2 D10N variant operates within the broader IL-17/Th17 pathway where multiple genetic loci converge. rs12191877 (HLA-C*06:02), the strongest psoriasis susceptibility variant, primarily affects T-cell recognition of self-antigens and is the main predictor of biologic response (especially ustekinumab). The combination of HLA-C*06:02 with TRAF3IP2 D10N creates a dual-hit: impaired immune tolerance (HLA) plus enhanced Th17 expansion with IL-22 skew (TRAF3IP2).

rs12188300 (IL12B) affects upstream Th17 differentiation through IL-12/IL-23 signaling. IL-23 drives Th17 commitment; when TRAF3IP2 D10N then removes the IL-17-dependent negative feedback on Th17 cells, the combination of enhanced Th17 differentiation (IL12B) and unregulated Th17 expansion (TRAF3IP2) may substantially amplify psoriasis susceptibility and plaque severity.

A compound action examining the interaction between rs33980500-T and rs12191877-T (HLA-C*06:02) would be appropriate: both genotypes should co-occur in the same individual for consideration of early dermatology referral and monitoring for biologic therapy eligibility, given substantially elevated combined psoriasis risk and pharmacogenomically relevant anti-IL-17 response modification.

Drug Interactions

secukinumab altered_response literature
ixekizumab altered_response literature
brodalumab altered_response literature
etanercept altered_response literature

Genotype Interpretations

What each possible genotype means for this variant.

CC Normal Act1 Function Normal

Standard IL-17 signaling with typical psoriasis risk

You have two copies of the common C allele, encoding aspartic acid at position 10 of the Act1 protein. Your Act1 maintains full interaction with Hsp90, TRAF6, TRAF2, and TRAF3, enabling normal IL-17 receptor signaling. IL-17-mediated inflammatory responses and Th17 cell regulation function as expected. This genotype is found in approximately 85% of European populations and over 97% of East Asian populations. Your baseline risk for psoriasis and psoriatic arthritis is at population average from this variant.

CT Reduced Act1 Function Intermediate

One copy of D10N partially impairs IL-17 signaling, moderately increasing psoriasis risk

The additive inheritance pattern means one T allele confers intermediate risk. Studies across 6+ European cohorts consistently replicated the heterozygous risk elevation. The functional impact is meaningful: in ex vivo assays, heterozygous individuals show intermediate Th17 induction compared to CC and TT homozygotes, and the effect is amplified in the presence of neutrophil extracellular traps (NETs) — relevant because psoriatic skin lesions contain abundant NETs.

The pharmacogenomic dimension matters for biologic therapy selection: heterozygous carriers of D10N have partially impaired IL-17 downstream signaling, which may influence how anti-IL-17 biologics engage their target pathway.

TT Impaired Act1 Function High Risk

Two copies of D10N substantially impairs IL-17 signaling and significantly elevates psoriasis risk

The homozygous state has been directly studied. In ex vivo neutrophil extracellular trap assays, TT homozygotes showed the most pronounced Th17 induction and IL-17A secretion, with NETs acting as a potentiating trigger. This models what occurs in psoriatic skin, where NETs from activated neutrophils in plaques drive further Th17 expansion in a genotype-dependent manner.

The Act1 D10N loss-of-function mechanism was fully characterized in reconstitution experiments: Act1-null cells transduced with D10N Act1 failed to restore any IL-17 signaling (no IκBα phosphorylation, no Erk/Jnk activation, no NF-κB). However, these same cells showed hyper-Th17 differentiation — more CD4+IL-17+ cells, higher RORC expression, and greater IL-17A release compared to Act1 wild-type controls. IL-22, not IL-17, is the primary downstream effector driving keratinocyte hyperproliferation in this genotype context.

The pharmacogenomic implications are most pronounced here. Anti-IL-17 biologics (secukinumab, ixekizumab, brodalumab) neutralize IL-17A or the IL-17RA receptor — but the downstream signaling component Act1 is already non-functional. The primary driver of skin inflammation in TT homozygotes is IL-22, not IL-17. This mechanistic distinction may explain why anti-IL-23 agents (guselkumab, risankizumab, tildrakizumab) or anti-IL-22 approaches could theoretically be more effective in D10N homozygotes, though prospective pharmacogenomic trials stratified by rs33980500 homozygosity have not yet been published.